| Literature DB >> 27299959 |
Rikki A Cannioto1, Michael J LaMonte2, Linda E Kelemen3, Harvey A Risch4, Kevin H Eng5, Albina N Minlikeeva1,2, Chi-Chen Hong1, J Brian Szender6, Lara Sucheston-Campbell1, Janine M Joseph1, Andrew Berchuck7, Jenny Chang-Claude8,9, Daniel W Cramer10, Anna DeFazio11, Brenda Diergaarde12, Thilo Dörk13, Jennifer A Doherty14, Robert P Edwards15,16, Brooke L Fridley17, Grace Friel18, Ellen L Goode19, Marc T Goodman20, Peter Hillemanns21, Estrid Hogdall22,23, Satoyo Hosono24, Joseph L Kelley15, Susanne K Kjaer22,25, Rüdiger Klapdor21, Keitaro Matsuo26, Kunle Odunsi6, Christina M Nagle27, Catherine M Olsen27, Lisa E Paddock28, Celeste L Pearce29, Malcolm C Pike30, Mary A Rossing31, Barbara Schmalfeldt32, Brahm H Segal33, Elizabeth A Szamreta34, Pamela J Thompson20, Chiu-Chen Tseng35, Robert Vierkant36, Joellen M Schildkraut37, Nicolas Wentzensen38, Kristine G Wicklund31, Stacey J Winham36, Anna H Wu35, Francesmary Modugno12,15,16, Roberta B Ness39, Allan Jensen22, Penelope M Webb27, Kathryn Terry10, Elisa V Bandera34, Kirsten B Moysich1.
Abstract
BACKGROUND: Little is known about modifiable behaviours that may be associated with epithelial ovarian cancer (EOC) survival. We conducted a pooled analysis of 12 studies from the Ovarian Cancer Association Consortium to investigate the association between pre-diagnostic physical inactivity and mortality.Entities:
Mesh:
Year: 2016 PMID: 27299959 PMCID: PMC4931371 DOI: 10.1038/bjc.2016.153
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Characteristics of the Ovarian Cancer Association Consortium studies included in the analyses (N=12 studies)
| Australian Ovarian Cancer Study/Australian Cancer Study (AUS) ( | Population-based case–control | Cases obtained via surgical treatment centres and cancer registries | 2002–2006 | 1016 | 7.5 (10.0) | 653 (64.3%) | Medical record review |
| Connecticut Ovary Study (CON) ( | Population-based case–control | Cases obtained via cancer registries and pathology departments | 1998–2003 | 381 | 8.4 (10.4) | 217 (57%) | Connecticut Tumor Registry and obituary listings in Connecticut newspapers |
| Diseases of the Ovary and their Evaluation (DOV) and (DVE) ( | Population-based case–control | Cases identified via SEER registry | 2002–2009 | 884 | 4.4 (8.9) | 350 (39.6%) | Standard US NCI SEER-registry follow-up methods |
| Hawaii Ovarian Cancer Case–Control Study (HAW) ( | Population-based case–control | Cases were identified via cancer registries | 1993–2008 | 359 | 7.2 (16.5) | 181 (50.4%) | Standard US NCI SEER-registry follow-up methods and medical record review |
| Hormones and Ovarian Cancer Prediction Study (HOP) ( | Population-based case–control | Cases identified via cancer registries, physician offices, and pathology databases | 2003–2008 | 506 | 5.1 (9.2) | 262 (51.8%) | Medical record review and Social Security database |
| Hospital-based Research Program at Aichi Cancer Center (JPN) ( | Hospital/Clinic-based case-control | Cases identified via cancer centre database | 2001–2005 | 51 | 5.0 (9.2) | 21 (41.2%) | Medical record review |
| Mayo Clinic Case-Only Ovarian Cancer Study (MAC) ( | Hospital/clinic-based case-only | Cases identified via Mayo Clinic Divisions of Surgical Gynecology & Medical Oncology | 2000–2011 | 83 | 2.9 (16.2) | 32 (38.6%) | Patient contact and vital statistics |
| MALignant OVArian cancer (MAL) ( | Population-based case–control | Cases identified via cancer registry and gynaecologic departments | 1994–1999 | 492 | 13.6 (16.0) | 371 (75.4%) | Danish Civil Registration System and Danish Register of Causes of Death |
| Mayo Clinic Ovarian Cancer Case-Control Study (MAY) ( | Hospital/clinic-based case–control | Cases recruited from Mayo Clinic | 2000–2008 | 519 | 3.4 (8.9) | 283 (54.5%) | Patient contact and vital statistics |
| New England Case Control Study (NEC) ( | Population-based case–control | Cases identified via hospital tumour boards and cancer registries | 1992–2008 | 785 | 13.4 (19.9) | 454 (57.8%) | Annual medical record review and death record database |
| New Jersey Ovarian Cancer Study (NJO) ( | Population-based case–control | Cases identified via New Jersey State Cancer Registry | 2004–2008 | 195 | 6.4 (11.2) | 110 (56.4%) | Linkage with the New Jersey State Cancer Registry |
| Los Angeles County Case–Control Studies of Ovarian Cancer-1 & 2 (USC) ( | Population-based case–control | Cases identified via LA County Cancer Surveillance Program | 1993–2009 | 1535 | 8.3 (18.0) | 823 (53.6%) | Standard US NCI SEER-registry follow-up methods |
Abbreviation: OCAC=Ovarian Cancer Association Consortium.
Study sites are listed in alphabetical order by OCAC study abbreviation.
Total participant numbers reflect invasive cases in the OCAC core data set (July 2014) with available vital status and recreational physical activity data.
Hazard ratios and 95% confidence intervals representing the association between recreational physical inactivity and mortality among women diagnosed with invasive EOC (N=6806; 12 studies)a
| All EOC cases | Age-adjusted | 2898 | 3907 | 1.13 | 1.04 | 1.22 | 0.005 |
| Multivariable | 2861 | 3876 | 1.22 | 1.12 | 1.33 | <0.001 | |
| Invasive high-grade serous | Age-adjusted | 2287 | 1902 | 1.16 | 1.05 | 1.27 | 0.002 |
| Multivariable | 2281 | 1900 | 1.21 | 1.11 | 1.33 | <0.001 | |
| Invasive low-grade serous | Age-adjusted | 104 | 213 | 1.16 | 0.77 | 1.75 | 0.479 |
| Multivariable | 103 | 213 | 1.30 | 0.89 | 1.96 | 0.219 | |
| Invasive mucinous | Age-adjusted | 85 | 380 | 1.21 | 0.77 | 1.91 | 0.410 |
| Multivariable | 85 | 379 | 0.93 | 0.59 | 1.49 | 0.773 | |
| Invasive endometrioid | Age-adjusted | 225 | 943 | 1.14 | 0.85 | 1.53 | 0.395 |
| Multivariable | 225 | 943 | 1.26 | 0.94 | 1.70 | 0.125 | |
| Invasive clear cell | Age-adjusted | 167 | 441 | 1.30 | 0.93 | 1.80 | 0.125 |
| Multivariable | 167 | 441 | 1.29 | 0.92 | 1.79 | 0.136 | |
Abbreviations: CI=confidence interval; EOC=epithelial ovarian cancer; HR=hazard ratio.
Numbers may not sum to total due to missing data.
Adjustment variables were identified based on well-established prognostic factors for EOC and the 10% change-in-estimate method.
Multivariable model is adjusted for age, stage, and histotype.
Multivariable model is adjusted for age and stage.
Residual disease-adjusted hazard ratiosa and 95% confidence intervals representing the association between recreational physical inactivity and mortality among women diagnosed with invasive EOC (N=2473; 7 studies)b
| All EOC cases | Age-adjusted | 1057 | 1135 | 1.28 | 1.13 | 1.46 | <0.001 |
| Multivariable #1 | 1055 | 1135 | 1.40 | 1.23 | 1.60 | <0.001 | |
| Multivariable #2 | 1055 | 1135 | 1.34 | 1.18 | 1.52 | <0.001 | |
| Invasive high-grade serous | Age-adjusted | 827 | 579 | 1.36 | 1.18 | 1.58 | <0.001 |
| Multivariable #1 | 826 | 579 | 1.41 | 1.22 | 1.64 | <0.001 | |
| Multivariable #2 | 826 | 579 | 1.35 | 1.17 | 1.57 | <0.001 | |
| Invasive low-grade serous | Age-adjusted | 61 | 80 | 0.90 | 0.54 | 1.51 | 0.698 |
| Multivariable #1 | 60 | 80 | 1.14 | 0.68 | 1.92 | 0.611 | |
| Multivariable #2 | 60 | 80 | 0.90 | 0.53 | 1.52 | 0.684 | |
| Invasive mucinous | Age-adjusted | 28 | 102 | 1.75 | 0.83 | 3.71 | 0.145 |
| Multivariable #1 | 28 | 102 | 1.27 | 0.59 | 2.72 | 0.538 | |
| Multivariable #2 | 28 | 102 | 1.14 | 0.52 | 2.46 | 0.749 | |
| Invasive endometrioid | Age-adjusted | 76 | 249 | 1.25 | 0.78 | 2.03 | 0.356 |
| Multivariable #1 | 76 | 249 | 1.17 | 0.73 | 1.90 | 0.514 | |
| Multivariable #2 | 76 | 249 | 1.09 | 0.67 | 1.77 | 0.720 | |
| Invasive clear cell | Age-adjusted | 65 | 125 | 1.73 | 1.06 | 2.84 | 0.029 |
| Multivariable #1 | 65 | 125 | 1.64 | 1.00 | 2.67 | 0.050 | |
| Multivariable #2 | 65 | 125 | 1.73 | 1.06 | 2.84 | 0.029 | |
Abbreviations: CI=confidence interval; EOC=epithelial ovarian cancer; HR=hazard ratio.
Hazard ratios represent mortality among participants with available residual disease data from seven studies (AUS, HAW, JPN, MAC, MAL, MAY, and NEC).
Numbers may not sum to total due to missing data.
Adjustment variables were identified based on well-established prognostic factors for EOC and the 10% change-in-estimate method.
Multivariable model #1 is adjusted for age, stage, and histotype; multivariable model #2 is adjusted for age, stage, histotype, and residual disease.
Multivariable model #1 is adjusted for age and stage; multivariable model #2 is adjusted for age, stage, and residual disease.